Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

Wu Y., Ma H., Zhu T., Huang S., Lu M., Wang Q.

Narrative Review on Autoimmune Research, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41677384
PMCID
PMC13042434
DOI
10.1002/advs.202521802

Abstract (original English)

Autoimmune diseases (ADs) are chronic disorders caused by a breakdown in immune self-tolerance, triggering aberrant immune attacks against one's own tissues. These responses cause persistent inflammation and multiorgan damage. As the global prevalence of ADs continues to increase, they impose a growing public health burden, but current treatments do not meet clinical needs. Extracellular vesicles (EVs) are lipid bilayer membrane-enclosed nanoparticles secreted by live cells that can carry diverse bioactive molecules and play essential roles in intercellular communication. Recently, EVs have attracted considerable attention as promising therapeutic candidates for ADs owing to their high biocompatibility, low immunogenicity, and ability to traverse biological barriers. This review systematically summarizes the current applications and development trends of both plant and mammalian sources and explores the functions of natural or engineered EVs in modulating the pathological processes underlying ADs. We also discuss the emerging potential of EVs as diagnostic biomarkers and targeted drug delivery systems for autoimmune conditions. Although clinical translation of EV-based therapies faces challenges, deepening our understanding of the pathogenic roles of EVs in autoimmunity coupled with ongoing advances in bioengineering technologies holds promise for delivering novel theoretical i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansAutoimmune DiseasesDrug Delivery SystemsBioengineeringBiomarkersExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research